Search results
Results from the WOW.Com Content Network
Gastroparesis (gastro- from Ancient Greek γαστήρ – gaster, "stomach"; and -paresis, πάρεσις – "partial paralysis") is a medical disorder of ineffective neuromuscular contractions (peristalsis) of the stomach, resulting in food and liquid remaining in the stomach for a prolonged period of time.
The condition can be caused by underlying medical issues, and one of the more common causes of gastroparesis is diabetes, according to the American College of Gastroenterology. It can also result ...
GLP-1 agonists were initially developed for type 2 diabetes. [5] The 2022 American Diabetes Association (ADA) standards of medical care in diabetes include GLP-1 agonists or SGLT2 inhibitors as a first-line pharmacological therapy for type 2 diabetes in patients who have or are at high risk for atherosclerotic cardiovascular disease or heart failure.
The first medication in this class, sitagliptin, received FDA approval in 2006 for the treatment of type 2 diabetes mellitus. The GLP-1 analogs principally act as agonists of the GLP-1 receptor and are thus insulinotropic. Exenatide was the first drug in this class to be used in the treatment of type 2 diabetes; it first received FDA approval ...
This condition is also called rapid gastric emptying. [1] It is mostly associated with conditions following gastric or esophageal surgery, though it can also arise secondary to diabetes or to the use of certain medications; it is caused by an absent or insufficiently functioning pyloric sphincter , the valve between the stomach and the duodenum.
2695 14607 Ensembl ENSG00000159224 ENSMUSG00000014351 UniProt P09681 P48756 RefSeq (mRNA) NM_004123 NM_008119 RefSeq (protein) NP_004114 NP_032145 Location (UCSC) Chr 17: 48.96 – 48.97 Mb Chr 11: 95.92 – 95.92 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Gastric inhibitory polypeptide (GIP), also known as glucose-dependent insulinotropic polypeptide, is an inhibiting hormone ...
By Sriparna Roy and Mariam Sunny (Reuters) -Advisers to the U.S. health regulator on Friday voted against the use of Novo Nordisk's weekly insulin in patients with type 1 diabetes due to risks of ...
In explaining the problem that could cause, the Mylan-written, FDA-posted recall notice says: “For patients receiving treatment with more than one type of insulin (e.g., both short and long ...